ClinicalTrials.gg
CompletedNCT05241535Updated May 15, 2023

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

A Phase 1 interventional study of MT-7117 and moxifloxacin in Healthy Subjects, sponsored by Mitsubishi Tanabe Pharma America Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by Mitsubishi Tanabe Pharma America Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of a single oral dose of MT-7117 on the QT/QTc interval in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Mitsubishi Tanabe Pharma America Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide written to participate in this study after reading the participant information sheet and Informed Consent Form (ICF) and having the opportunity to discuss the study with the Investigator or designee.
  2. Healthy male or female subjects, 18-45 years of age, inclusive, at the time of signing the ICF.
  3. Subjects must weigh at least 50 kilograms (kg) (110 pounds) but no more than 95 kg (209 pounds) and have a (BMI) 18.0 to 30.0 kg/m2 both inclusive at Screening and on Day -1.
  4. Female subjects must not be lactating and must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours before receiving the first dose of IMP ( Medicinal Product).
  5. Female subjects of and male subjects with a partner of childbearing potential must agree to use 2 effective methods of (in female subjects, one method must be highly effective).
  6. Male subjects must agree not to donate sperm and female subjects must agree not to donate ova until 3 months after the last dose of IMP.
  7. In the Investigator's opinion, the subject can understand the nature of the study and any risks involved in participation and is willing to cooperate and comply with the protocol restrictions and requirements.

Exclusion criteria

Exclusion Criteria:

  1. Presence or history of any hepatobiliary disease at Screening, determined by the Investigator after discussion with Sponsor's Responsible Physician. Current, or history of, clinically significant (in the opinion of the Investigator and Sponsor Responsible Physician) endocrine, respiratory, neurological, gastrointestinal, renal, cardiovascular disease, or history (within the last 2 years) of any clinically significant psychiatric/psychotic illness disorder (including anxiety, depression, and reactive depression).
  2. Clinically relevant abnormal medical history, physical findings or laboratory values at Screening or Day -1 that could interfere with the objectives of the study or the safety of the subject, as judged by the Investigator.
  3. Subject with a history of gastrointestinal surgery or disease known to affect absorption, metabolism, or excretion of the IMP (other than surgical history of appendectomy and hernia repair / herniorrhaphy / hernioplasty are permitted).
  4. Subjects who have had major surgery within 3 months of Day 1.
  5. Family history of long or short syndrome, hypokalemia, syncope, or Torsades de Pointes.
  6. Clinically significant 12-lead abnormalities, including subjects with QTcF of ≥450 msec at Screening or Day -1. A repeat assessment is allowed at each visit. If the repeat measurement is in range, the subject may be included.
  7. Subjects with (AST), alanine aminotransferase (ALT), or ≥1.5 × reference range at Screening or Day -1. A repeat assessment is allowed at each visit. If the repeat measurement is in range, the subject may be included.
  8. Blood pressure (supine) at Screening or Day -1 outside the range 90-145 mmHg (systolic) or 50-95 mmHg (diastolic); and resting heart rate (HR) outside the range of 45-100 bpm. A repeat assessment is allowed at each visit. If the repeat measurement is in range, the subject may be included.
  9. Receipt of any prescribed or nonprescribed systemic or topical medication within 30 days (or, if relevant, 5 half-lives, whichever is longer) prior to the first dose of study drugs unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise subject safety.

    1. Occasional use of paracetamol (acetaminophen) for mild analgesia is permitted.
    2. Vitamins and herbal supplements are not permitted 14 days prior to dosing.
  10. Presence or history of severe adverse reaction or allergy to any drug or or other allergies that are of clinical significance to the study drugs.
  11. Previously having received MT-7117.
  12. History or presence of melanoma and/or lesions suspicious for melanoma at Screening.

    a. Subjects with the presence of a skin lesion suspicious for dysplastic nevus or a history of proven dysplastic nevus.

  13. Subjects with a first-degree relative with a history of familial melanoma.
  14. Subjects who have previously received afamelanotide or melanotan.
  15. Subjects who test positive for surface antigen, hepatitis B core antibody, antibody, or (HIV) 1 and HIV 2 antibodies at Screening.
  16. Subjects who have had coronavirus disease 2019 (COVID-19) in the 3 months prior to Screening; or suspected active COVID-19 infection, a positive COVID-19 test, contact with an individual with known COVID-19, or travel to an area with a high risk of COVID-19 infection within 14 days of Screening or Day 1.

    1. Subjects who have received a COVID-19 vaccination within 14 days of Day 1. COVID-19 vaccination is not permitted during the study. Subjects may not take part in the study if they have started but not completed a COVID-19 vaccination course at the time of Screening or Day -1. Subjects who do not plan to complete the COVID-19 vaccination course will be allowed to participate in the study as long as at least 14 days have elapsed since the last vaccination.
    2. Subjects who test positive for COVID-19 at Day -1.
    3. Subjects currently suffering from clinically significant prolonged COVID symptoms.
  17. Presence or history of drug abuse (as defined by [DSM-V] criteria), or a positive urine test for drugs of abuse at Screening or Day 1.
  18. Presence or history (in the last 2 years) of alcohol abuse or excessive alcohol consumption, defined as subjects who regularly, or on average, drink more than 21 units (168 grams) for males or 14 units (112 grams) for females, of alcohol per week (1 unit is equivalent to 8 grams of alcohol).
  19. Subjects who use tobacco or nicotine-containing products (snuff, chewing tobacco, cigarettes, cigars, pipes, e-cigarettes, or nicotine replacement products) within 3 months prior to dosing, or positive urine cotinine test at Screening or Day -1.
  20. Consumption of food or drink containing licorice, oranges, or grapefruit from 7 days prior to dosing with IMP.
  21. Subjects who are not willing to abstain from the consumption of caffeine and methylxanthine (e.g., coffee, tea, cola, energy drinks, or chocolates) in the 48 hours before Day -1 until completion of the post-treatment assessments on Day 2.
  22. Donation of 1 or more units of blood (≥450 milliliters) in the 3 months prior to Screening, or plasma in the 7 days prior to Screening, or in the 6 weeks prior to Screening, or intention to donate blood within 3 months after the last scheduled visit.
  23. Heavy physical training, excessive exercise or heavy labor (e.g., long-distance running, weightlifting, or any physical activity to which the subject is not accustomed) from 3 days before the administration of the study drug.
  24. Participation in any study* involving administration of an IMP within 8 weeks (or, if relevant, 5 half-lives, whichever is the longer) prior to the first dose. (*Disregarding any study Follow-up Periods).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Sequence 1 (starting with MT-7117 or Placebo)

    Treatment A or B (a single oral dose of MT-7117 or Placebo), Treatment C (a single oral dose of moxifloxacin)", then Treatment A or B (a single oral dose of placebo or MT-7117).

    Drug: MT-7117 · Drug: moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 2 (starting with MT-7117 or Placebo)

    Treatment A or B (a single oral dose of placebo or MT-7117), Treatment A or B (a single oral dose of MT-7117 or Placebo), then Treatment C (a single oral dose of moxifloxacin).

    Drug: MT-7117 · Drug: moxifloxacin · Drug: Placebo

  • Experimental
    Sequence 3 (starting sequence with Moxifloxacin)

    Treatment C (A single oral dose of moxifloxacin), Treatment A or B (a single oral dose of placebo or MT-7117), then Treatment A or B (a single oral dose of MT-7117 or Placebo).

    Drug: MT-7117 · Drug: moxifloxacin · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Placebo-corrected, baseline-adjusted QTcF (corrected QT interval using the Fridericia formula) interval (ΔΔQTcF) at designed time points up to 24 hours post-dose

    The upper bound of the one-sided 95% confidence interval (CI) for the ΔΔQTcF at geometric mean Cmax (maximum plasma concentration) level is \<10 milliseconds.

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

Secondary outcomes

  1. Absolute values and changes in QTcF interval, PR (retrograde P waves), and QRS (Q wave, R wave, and S wave) values from Baseline at each timepoint.

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  2. Absolute values and changes in heart rate (HR) from Baseline at each timepoint.

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  3. The lower bound of the one-sided 95% CI of the ΔΔQTcF is >5 milliseconds at one or more individual timepoints between 1 hour and 4 hours after a single dose of moxifloxacin.

    Assay sensitivity.

    Time frame: 1 hour post dose, 2 hours post dose, 3 hours post dose and 4 hours post dose

  4. The slope in concentration-response analysis for moxifloxacin is significantly positive from zero and the lower bound of the two-sided 90% CI of the predicted ΔΔQTcF at the geometric mean Cmax exceeds 5 milliseconds.

    Assay sensitivity.

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  5. Proportion of subjects with a QTcF interval >=450, >=480, and >=500 milliseconds.

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  6. Proportion of subjects with an increase from baseline in QTcF interval of >30 and >60 milliseconds.

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  7. Proportion of subjects with HR, PR interval, or QRS duration abnormalities.

    HR \< 40 bpm (bits per minute) after a decrease of HR\>=20 bpm from Baseline, or HR \> 110 bpm after an increase of HR\>=20 bpm from Baseline. PR interval of \<100 milliseconds after a decrease of PR interval \>= 25% from Baseline, or PR interval of \>220 milliseconds after an increase of PR interval \>= 25% from Baseline. QRS duration \>120 milliseconds. Change of QRS duration \>= 25% from baseline reaching a QRS \>=120 milliseconds.

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  8. Proportion of subjects with an emergent ECG (Electrocardiogram) diagnostic abnormality.

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  9. Plasma concentration versus time profile of MT-7117 after dosing.

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  10. Plasma PK (Pharmacokinetics) parameters for MT-7117; maximum plasma concentration (Cmax)

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  11. Plasma PK parameters for MT-7117; time to maximum concentration (tmax)

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  12. Plasma PK parameters for MT-7117; area under the plasma concentration-time curve from zero to the last quantifiable concentration timepoint (AUC0-last)

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  13. Plasma PK parameters for MT-7117; area under the plasma concentration-time curve from zero to 24 hours (AUC0-24)

    Time frame: Pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

  14. Treatment-emergent AEs (Adverse Events) (including serious AEs [SAEs] and hepatic AEs of special interest [AESIs]).

    Time frame: Day-1 to Day 5 after Period 3.

07

Study locations

2 sites
  • Daytona Beach Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Dallas Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Feb 2022, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2022
First posted
Feb 15, 2022
StartActual
Jan 12, 2022
Primary completionActual
Feb 23, 2022
CompletionActual
Feb 27, 2022
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05241535
Responsible party
Sponsor
First posted
Feb 15, 2022
Start date
Jan 12, 2022
Primary completion
Feb 23, 2022
Completion
Feb 27, 2022
Last update
May 15, 2023

Study contacts

Head of Medical Science
study director · Mitsubishi Tanabe Pharma America Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion